Iloprost: profile and news
CoTherix to Host Conference Call on March 8, 2006 to Announce ... Feb 23, 2006
CoTherix's Ventavis(R) (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - PR Newswire (press release),
CoTherix to Webcast Presentation From Merrill Lynch Conference Jan 30, 2006
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - Yahoo! News (press release)
CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ... Jan 19, 2006
...(Nasdaq: CTRX - News) today announced that preliminary net product sales of Ventavis®(iloprost) Inhalation Solution in the fourth quarter of 2005 totaled ... - Yahoo! News (press release)
CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ... Jan 19, 2006
19 /PRNewswire-FirstCall/ -- CoTherix, Inc. (NASDAQ:CTRX) today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in ... - Biotech Intelligence (press release),
CoTherix Announces Fourth Quarter Ventavis Sales and 2006 Revenue ... Jan 19, 2006
...today announced that preliminary net product sales of Ventavis(R)(iloprost) Inhalation Solution in the fourth quarter of 2005 totaled approximately $11.0 ... - PharmaLive.com (press release),
Vanderbilt-Ingram Cancer Center testing new lung cancer treatment Nov 18, 2005
The study will look at the effects of the investigational drug Iloprost, which is used to treat pulmonary hypertension and peripheral vascular disease, which ... - Nashville Business Journal,
Zacks Industry Outlook Highlights: Bio-Rad Labs, Gilead Sciences ... Dec 1, 2005
...consensus. The company's Ventavis(R) (iloprost) Inhalation Solution watched net product sales more than double to $8.4 million. ... - Business Wire (press release),
CoTherix, Inc. Announces Follow-On Offering of 4,500,000 Shares of ... Oct 6, 2005
CoTherix's Ventavis(R)(iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (PAH) in ... - PR Newswire (press release),
"Wonder Drugs" May Work Wonders for Pulmonary Arterial ... Sep 30, 2005
...taking Gleevec, the patient described in the case report continued on his other medications, including Tracleer (bosentan), Ventavis (iloprost), Viagra, oral ... - MedPage Today,
Respironics Receives 510(k) Clearance From FDA for I-neb(TM) AAD(R ... Sep 28, 2005
In August 2005, FDA approved the use of the I-neb for the delivery of CoTherix's Ventavis(R) (iloprost) Inhalation Solution for the treatment of pulmonary ... - PR Newswire (press release),
FDA Grants Expanded Label for Ventavis Aug 30, 2005
...announced today that it has received approval from the US Food and Drug Administration (FDA) to modify the Ventavis® (iloprost) Inhalation Solution label to ... - Yahoo News (press release)
CoTherix to Webcast Presentations From Two Upcoming Investor ... Aug 29, 2005
CoTherix's Ventavis® (iloprost) Inhalation Solution was approved by the FDA in December 2004 for the treatment of pulmonary arterial hypertension (World ... - Yahoo News (press release)
Colorado At Forefront Of Lung Cancer Battle Aug 10, 2005
...starts. "We have a very big trial of a novel agent called Iloprost to prevent lung cancer in people who are at high risk," Bunn said. ... - cbs4denver.com,
Inhaled drug takes aim at serious lung disease Aug 15, 2005
Until now, prostacyclin had to be given through a permanently implanted catheter, but a new formulation, called iloprost, is inhaled. ... - Macleans,
